Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3122540 | 0.85 | ATM (0.51) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL3639839 | 0.82 | HTR2A (0.51) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL22431758 | 0.78 | ATM (0.45) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL19214856 | 0.76 | ATM (0.46) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL873512 | 0.75 | CYP1A2 (0.54) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL3634029 | 0.74 | ATM (0.47) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL3959593 | 0.73 | ATM (0.44) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL22144964 | 0.73 | ATM (0.41) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL17573000 | 0.72 | ATM (0.46) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL20132769 | 0.72 | PDE10A (0.55) | CYP1A2PDE10AMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428065-B2 | Isoxazolyl substituted imidazopyridines | CELLCENTRIC LTD (GB) | 2019-10-01 | — | — | US | disclosed |
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2018-04-19 | — | — | US | disclosed |
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | EP300, HDAC3, HDAC1 | ATM 898/4885L3MBTL1 1692/4885CYP1A2 2584/4885 |
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | EP300, HDAC3, HDAC1 | ATM 557/4885L3MBTL1 1462/4885CYP1A2 2680/4885 |
| US-10428065-B2 | Isoxazolyl substituted imidazopyridines | EP300, HDAC3, HDAC1 | ATM 898/4885L3MBTL1 1692/4885CYP1A2 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.